Carasent Q2’22: Initial take

Research Note

2022-07-15

08:57

Redeye comments on Carasent's Q2 2022 report, which came in slightly lower than our estimates on the top line and margins. The bright spot was instead the newly signed clinics, and the launch of Webdoc NO in Norway.

Mark Siöstedt

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.